Search PubMed⌕ Search

Biomedical subjects

R V Lewis

Publications and source records attributed to R V Lewis.

At least 73 records · Page 4Linked to original sources

Rattlesnake presynaptic neurotoxins: primary structure and evolutionary origin of the acidic subunit.

Crotoxin and homologous crotalid presynaptic neurotoxins consist of a toxic, basic subunit and a slightly smaller, nontoxic, acidic subunit. The latter, in turn, consists of three chains, interconnected by disulfide bonds. The complete sequences of two of the three acidic subunit chains of crotoxin, from the venom of the South American rattlesnake Crotalus durissus terrificus, have been determined. In addition, all but the ten amino-terminal residues of the third chain have been sequenced. Sequence comparison data suggest that the acidic subunit has been derived from a nontoxic, homodimeric, crotalid phospholipase A2. When compared with sequences of phospholipases A2, the acidic subunit lacks a 22-residue amino-terminal segment and two additional segments that are implicated in phospholipid substrate binding. However, it apparently retains an intact active site, the calcium binding loop, and segments involved in subunit binding in homodimeric phospholipases A2. The C chain of the acidic subunit shows strong homology with mammalian neurophysins, lending possible support to the hypothesis that the acidic subunit functions as a chaperone to prevent nonspecific binding of the toxic basic subunit. Crystals suitable for X-ray diffraction studies have recently been produced [Achari, A., Radvanyi, F. R., Scott, D., Bon, C., & Sigler, P. B. (1985) J. Biol. Chem. 260, 9385-9387]; thus with these data it should now be possible to determine the three-dimensional structure of the intact neurotoxin and dissociated subunits.

Amino Acid Sequence↗

The amino terminal sequences of bovine and human chromogranin A and secretory protein I are identical.

The amino terminal sequences of bovine and human adrenal medullary chromogranin A have been determined. Their sequences are identical and also identical to the published sequence of secretory protein I from the parathyroid gland. This data indicates that the previously published sequence of chromogranin A is incorrect at residues 2 and 19. These data confirm earlier observations of a substantial similarity between secretory protein I and chromogranin A and, in fact, strongly suggest that they are identical.

Amino Acid Sequence↗

Side-effects of beta-blockers assessed using visual analogue scales.

Visual analogue scales were used in a pilot study to compare side-effects in patients receiving antihypertensive drugs either including or excluding beta-blockers. Compared with symptom scores for patients receiving antihypertensive medication other than a beta-blocker, symptom scores (when combined) for patients receiving a beta-blocker were significantly higher for tired legs (p less than 0.001), cold digits (p less than 0.005), and vivid dreams (p less than 0.01). These methods were also applied in a postal survey which was designed to compare the incidence of symptoms in patients receiving different beta-blockers with symptoms in subjects receiving no drugs. When compared with symptom scores for subjects receiving no drugs, symptom scores (when combined) for patients receiving beta-blockers were significantly higher for tired legs (p less than 0.001), cold digits (p less than 0.01), insomnia (p less than 0.01), and lack of well-being (p less than 0.01). These two studies were consistent in showing higher symptom scores for tired legs and cold digits in patients receiving beta-blockers. However, there were inconsistencies regarding sleep disturbance. Increased dreaming was apparent in the pilot study whereas increased insomnia was apparent from the postal survey. These inconsistencies cannot be explained. No significant differences in side-effects were apparent between different beta-blockers.

Acebutolol↗

Response of plasma proenkephalin peptide F to exercise.

Plasma proenkephalin Peptide F immunoreactivity was measured in the plasma of endurance trained and untrained males at various exercise intensities. Significantly different levels were found between the two groups at rest and at 54% maximum oxygen consumption (VO2 max). Maximum levels were at 5 min of recovery for the untrained group and at 54% VO2 max and at recovery 5 min for the trained group. These data suggest an adaptation in the trained group fro the release of this peptide and further suggest it may play a role in recovery since the highest levels are following the termination of the exercise period.

Adult↗

Changes in plasma proenkephalin peptide F and catecholamine levels during graded exercise in men.

Proenkephalin peptide F immunoreactivity, epinephrine, and norepinephrine were measured in the plasma of endurance-trained and untrained male subjects riding on a bicycle ergometer at 28%, 54%, 83%, and 100% of maximum oxygen consumption (VO2). At rest the trained group had peptide F levels almost twice the level of the untrained group, whereas all other variables measured were the same. The maximum epinephrine and norepinephrine levels were found at 100% exercise intensity, with a precipitous drop in the levels at 5 min of recovery. In contrast, the peptide F immunoreactivity reached a maximum at 5 min of recovery and was still substantially above the initial level after 15 min of rest. In addition, the trained subjects showed another peak of peptide F immunoreactivity at 54% VO2max. Possible explanations for the different patterns of catecholamine and peptide F levels are presented.

Adult↗

The structure of caltrin, the calcium-transport inhibitor of bovine seminal plasma.

The amino acid sequence of the bovine seminal protein, caltrin, which inhibits calcium transport into spermatozoa, has been determined. The protein contains 47 amino acid residues. Parts of the sequence are identical with that reported for bovine seminal plasmin, a protein possessing antibacterial activity. We believe the proteins are identical and that the previously reported sequence of seminal plasmin is in error.

Amino Acid Sequence↗

Side-effects of beta-adrenoceptor blocking drugs assessed by visual analogue scales.

A series of visual analogue scales (VAS) was used to examine the prevalence of side-effects among hypertensive patients taking beta-adrenoceptor blocking drugs. When compared to untreated non-hypertensive control subjects, patients taking beta-adrenoceptor blockers had a greater prevalence of tired legs (P less than 0.001), cold digits (P less than 0.01), insomnia (P less than 0.01) and loss of overall wellbeing (P less than 0.01). Side-effects did not differ significantly between patients taking atenolol (n = 30), oxprenolol (n = 16), propranolol (n = 15) or metoprolol (n = 10). If there is an important difference in the prevalence of side-effects between different beta-adrenoceptor blockers, a much larger study will be needed to demonstrate it.

Adrenergic beta-Antagonists↗

Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics.

The pharmacokinetics and pharmacodynamics of atenolol and timolol were studied in six extensive and four poor metabolisers of debrisoquine. There was a significant correlation between the debrisoquine to 4-hydroxydebrisoquine ratio and the area under the plasma concentration time curve (AUC) for timolol (rs = 0.75, P less than 0.02). The mean of the AUC values for timolol was significantly greater in the poor metabolisers than in the extensive metabolisers (P less than 0.05). There was a significant correlation between the debrisoquine to 4-hydroxydebrisoquine ratio and beta-adrenoceptor blockade 24 h after dosing with timolol (rs = 0.66, P less than 0.05). The mean degree of beta-adrenoceptor blockade was significantly greater in the poor metabolisers than in the extensive metabolisers 24 h after dosing with timolol (P less than 0.01). There was no relation between the debrisoquine to 4-hydroxydebrisoquine ratio and the pharmacokinetics or pharmacodynamics of atenolol.

Adrenergic beta-Antagonists↗

Measuring side-effects of beta-adrenoceptor antagonists: a comparison of two methods.

The prevalence of side-effects of beta-adrenoceptor antagonists among hypertensive patients was assessed by two methods. Using visual analogue scales, scores for tired legs, cold digits and vivid dreaming were significantly higher in patients taking beta-adrenoceptor blockers than in patients not taking beta-adrenoceptor blockers. When measured by numerical scales, from 1 to 10, these symptoms showed no relation to beta-adrenoceptor blocker treatment. The visual analogue scales were more sensitive than the numerical scales because the scores were distributed more evenly over the analogue scales.

Adrenergic beta-Antagonists↗

New bovine adrenal medullary peptide and its precursor.

We have isolated a previously unknown peptide and its precursor from bovine adrenal medullary chromaffin granules. The peptide sequence is Leu-Pro-Val-Asn-Ser-Pro-Met-Asn-Lys-Gly-Asn-Glu-Val-Met-Lys. The peptide is cleaved from the precursor at a Lys site. The sequence shows no homology to any known protein in the largest sequence data bank available.

Adrenal Medulla↗

Purification and sequence of a novel ovine adrenal medullary peptide and its precursor.

A 24 amino acid polypeptide that does not originate from (pre)proenkephalin has been isolated from ovine adrenal chromaffin granules. Its sequence is: Arg-Leu-Pro-Gly-Glu-Leu-Arg-Asn-Tyr-Leu-Asp-Tyr-Gly-Glu-Glu-Val-Gly-Glu- Glu-Ala -Ala-Arg-Gly-Val. This peptide is generated from a precursor molecule that has also been purified and partially sequenced. The proteolytic cleavage occurs at a triple Arg site. A search of the available protein sequence data banks shows very little homology to any known protein.

Adrenal Medulla↗

Protein conformation and reversed-phase high-performance liquid chromatography.

The structure of a series of proteins has been investigated by circular dichroism, fluorescence and visible spectroscopy as well as by differential scanning calorimetry under reversed-phase high-performance liquid chromatography elution conditions. These studies show that 1-propanol, a typical eluent, induces a reversible conformational change in proteins to an apparently ordered, helical form. This structural transition occurs in the range of propanol concentrations that produces elution of a particular protein. The possible relationship between this conformational change and protein elution is considered.

1-Propanol↗

Purification and sequence of an opioid peptide derived from ovine proenkephalin.

An enkephalin-containing peptide originating from ovine adrenal proenkephalin has been purified and sequenced. The sequence of the peptide is: GLY-GLY-GLU-VAL-LEU-GLY-LYS-ARG-TYR-GLY-GLY-PHE-MET (preproenkephalin 128-140) which represents a portion of peptide F (preproenkephalin 107-140). This peptide has a sequence identical to that of bovine preproenkephalin 128-140 while it differs from the corresponding human sequence in positions 129, 131 and 133.

Adrenal Cortex↗

Adrenal medullary chromaffin granule peptides: two major ovine peptides and their precursor.

An octapeptide and decapeptide which are not derived from proenkephalin were isolated from ovine adrenal chromaffin granules. Their sequences are Asn-Leu-Asp -Pro-Lys-Leu-Asp-Leu and Val-Ala-Glu-Leu-Asp-Gln-Leu-Leu-His-Tyr. These two peptides were found to be derived from a single precursor peptide which has also been isolated and sequenced. The proteolytic cleavage occurs at a Lys-Arg site typical of prohormone to hormone cleavages.

Adrenal Medulla↗

Quantification of side-effects of beta-adrenoceptor blockers using visual analogue scales.

We have devised a series of visual analogue scales (VAS) to measure the side-effects prevalent amongst hypertensive patients taking beta-adrenoceptor blockers, and we present the results of a pilot study. These show that the method is suitable for studying side-effects and suggest that patients on beta-adrenoceptor blockers experience a greater incidence of tiredness of the legs, (P = 0.001), cold digits (P = 0.005) and vivid dreaming (P = 0.01) when compared to hypertensive patients not taking beta-adrenoceptor blockers.

Adrenergic beta-Antagonists↗

Isolation and sequence of a non-opioid peptide derived from proenkephalin.

A non-opioid peptide derived from adrenal proenkephalin has been isolated and sequenced. The sequence of this peptide is Ser-Pro-His-Leu-Glu-Asp-Glu-Thr-Lys-Glu-Leu-Gln (Proenkephalin 168-180). This sequence represents the portion of Peptide I that is cleaved to yield Peptide E. This peptide is processed in a similar manner to the opioid peptides and is present at approximately the same level as Peptide E.

Adrenal Glands↗